Comparative Pharmacology
Head-to-head clinical analysis: SYNAREL versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNAREL versus ZOLADEX.
SYNAREL vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH). Binds to pituitary GnRH receptors, initially stimulating then desensitizing them, leading to suppressed LH and FSH secretion, decreased gonadal steroid production (estrogen, testosterone).
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
200 mcg intranasally twice daily (400 mcg total daily dose) for 6 months. Initiate on day 5 of menstural cycle.
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
Terminal elimination half-life: ~3 hours (range 2-5 hours) after intranasal administration; clinically, dosing every 12 hours maintains therapeutic levels.
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Renal: ~90% as parent drug and metabolites; fecal: <10%.
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist